2024-516532-97-00
进行中（未招募）
1/2 期
A Phase 1/2, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients with Locally-Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Previously Received Platinum-Based Systemic Chemotherapy
概览
- 阶段
- 1/2 期
- 状态
- 进行中（未招募）
- 入组人数
- 63
- 试验地点
- 20
- 主要终点
- 1. Phase 1: The rate and severity of treatment emergent AEs (TEAEs), SAEs, incidence of safety laboratory assessment abnormalities
概览
简要总结
- Phase I : *Assess safety, tolerability and define maximum tolerated dose (MTD) of orally administered CLN-081.
- Phase 2a - Dose Expansion: *Evaluate objective response rate (ORR) and define recommended phase 2 dose (RP2D) of orally administered CLN-081.
- Module A
- Investigate PK profile of single doses of CLN-081 with or without a high fat meal in patients with solid tumors.
- Module B, Part 1:
- Define safety, tolerability and PK profile of CLN-081 administered as repeat doses BID with food to patients with locally-advanced or metastatic NSCLC harboring EGFR ex20ins mutations. *Investigate effect of food on CLN-081 tolerability BID.
- Module B, Part 2:
- Evaluate ORR and duration of response (DOR) by ICR of orally administered CLN-081 at RP2D.
- Module C:
- Evaluate ORR and DOR by ICR of orally administered CLN-081 BID in patients whose disease has progressed after prior treatment with an agent for the treatment of EGFR ex20ins mutant NSCLC.
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Histologically or cytologically confirmed locally advanced or metastatic NSCLC (all patients). For module A only, histologically or cytologically confirmed solid tumor with the exception of esophageal, gastric, pancreatic, hepatobiliary, or small bowel carcinomas, or history of gastric resection.
- •For Module B and Module C patients only: verification of suitable archived tumor tissue available at the participating center for biomarker analysis. A fresh biopsy is required if an archived sample is not available.
- •Ability to understand and the willingness to sign a written informed consent document.
- •Documented EGFR exon 20 insertion (ex20ins) mutation demonstrated by a validated test (per protocol) and performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified or equivalent laboratory (all patients other than Module A Food Effect PK Assessment Module).
- •Prior treatment in the recurrent/metastatic disease setting including: a) A platinum-based chemotherapy regiment (or other chemotherapy regimen if platinum-based chemotherapy is contra-indicated). b) Any other approved standard therapy that is available to the patient, unless this therapy is contraindicated, intolerable to the patient, or is declined by the patient. In the case of a patient declining such therapy, documentation that the patient has been informed and declined should be documented in the medical record. c) No prior therapy is required for patients enrolled on Module A. d) Prior therapy with an agent approved by the local regulatory authorities for the treatment of EGFR ex20ins mutant NSCLC (Module C only).
- •Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (except for patients enrolled on Module A).
- •Age ≥ 18 years.
- •Eastern Cooperative Oncology Group (ECOG) performance status 0 or
- •Ability to take pills by mouth.
- •Have the following laboratory values: a) Serum creatinine < 1.5 × upper limit of normal (ULN) or calculated creatinine clearance (CrCl) must be ≥ 50 mL/min/1.73 m2 (if calculated by Cockroft-Gault formula, the actual body weight must be used for CrCl unless body mass index [BMI] >30 kg/m2 then lean body weight must be used). b) Total bilirubin ≤ 1.5 × ULN unless prior history of Gilbert's syndrome. c) AST and ALT ≤ 2.5 × ULN, or ≤ 5 × ULN if due to liver involvement by tumor. d) Hemoglobin ≥ 9.0 g/dL in the absence of transfusion ≤ 14 days prior to the first dose of study drug on C1D
排除标准
- •R6, Phase 1 Expansion, Phase 2a, Module A and Module B Patients Only: Prior treatment with an EGFR ex20ins-targeting drug (see protocol for examples). Note: enrolment of patients treated previously with EGFR ex20ins-targeting drugs allowed selectively during accelerated titration dose escalation and Module C only.
- •All Patients: Have any condition or illness that, in the opinion of the Investigator might compromise patient safety or interfere with the evaluation of the safety of the drug.
- •All Patients: Pregnant or lactating females; FOCBP must have a negative serum pregnancy test at within seven days prior to receiving study drug on C1D
- •FOCBP and males with partners of child-bearing potential must agree to use adequate birth control throughout their participation and for six months following the last dose of study treatment.
- •Module A Patients Only: Conditions that compromise esophageal or gastrointestinal (GI) function.
- •All Patients: History of another primary malignancy within 2 years prior to starting study drug on C1D1, except for adequately treated basal or squamous cell carcinoma of the skin or cancer of the cervix in situ.
- •All Patients: Uncontrolled intercurrent illness including, but not limited to, uncompensated respiratory, cardiac, hepatic, or renal disease, active infection (including HIV and active clinical tuberculosis), or renal transplant; ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, or psychiatric illness/social situations that would limit compliance with study requirements.
- •All Patients: For patients with a history of HBV, negative PCR test is required. Patients with active HBV infection. Patients ineligible due to detectable levels of HBV DNA at baseline may be rescreened for enrolment if their HBV DNA levels become undetectable after treatment with antiviral agents, and upon agreement between the Investigator and Sponsor.
- •All Patients: For patients with a history of hepatitis C, active infection as defined by a reactive HCV antibody test and detectable HCV RNA.
- •All Patients: Active bleeding disorders.
结局指标
主要结局
1. Phase 1: The rate and severity of treatment emergent AEs (TEAEs), SAEs, incidence of safety laboratory assessment abnormalities
1. Phase 1: The rate and severity of treatment emergent AEs (TEAEs), SAEs, incidence of safety laboratory assessment abnormalities
2. Phase 2a: ORR by investigator assessment per RECIST v1.1
2. Phase 2a: ORR by investigator assessment per RECIST v1.1
3. Module A: CLN-081 PK
3. Module A: CLN-081 PK
4. Module B, Part 1: *The rate and severity of TEAEs, DLTs, SAEs, incidence of safety laboratory assessment abnormalities; *CLN-081 PK
4. Module B, Part 1: *The rate and severity of TEAEs, DLTs, SAEs, incidence of safety laboratory assessment abnormalities; *CLN-081 PK
5. Module B, Part 2 and 6. Module C: * ORR by independent central review assessment per RECIST v1.1; * Tumor response characteristics including DOR by independent central review
5. Module B, Part 2 and 6. Module C: * ORR by independent central review assessment per RECIST v1.1; * Tumor response characteristics including DOR by independent central review
次要结局
- 1. Phase 1: a) ORR by Investigator assessment per RECIST v1.1 b) DOR, DCR, PFS, and OS by investigator assessment c) CLN-081 PK
- 2. Phase 2a: a) DOR, DCR, PFS, time to tumor response, and OS based on investigator assessment b) The rate and severity of TEAEs, SAEs, incidence of safety laboratory assessment abnormalities c) CLN-081 PK
- 3. Module A: a) The rate and severity of TEAEs, SAEs, incidence of safety laboratory assessment abnormalities
- 4. Module B, Part 1: a) ORR based on independent central review assessment per RECIST v1.1 b) Tumor response characteristics including DOR, DCR, PFS, and time to tumor response based on local investigator assessment and OS
- 5. Module B, Part 2: a) ORR and DOR by Investigator assessment b) DCR, median PFS, rate of PFS and OS at 6, 12 and 24 months based on independent central review and investigator assessment and OS c) The rate and severity of TEAEs, DLTs, SAEs, incidence of safety laboratory assessment abnormalities d) CLN-081 PK
- 6. Module C: a) ORR and DOR by Investigator assessment per RECIST v1.1 b) Tumor response characteristics including DCR, PFS, and time to tumor response assessed by independent central review and investigator assessment and OS c) The rate and severity of TEAEs, DLTs, SAEs, incidence of safety laboratory assessment abnormalities d) CLN-081 PK
研究者
Study Responsible Physician
Scientific
Cullinan Pearl Corp.
研究点 (20)
Loading locations...
相似试验
招募中
1 期
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid TumorsNCT07261631Novartis Pharmaceuticals180
招募中
1 期
A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid TumorNCT07275242Suzhou Suncadia Biopharmaceuticals Co., Ltd.107
尚未招募
不适用
A Study of DB-1324 in Advanced/Metastatic Gastrointestinal TumorsNCT07263594DualityBio Inc.127
招募中
1 期
KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaDiffuse Large B Cell Lymphoma (DLBCL)NCT07260812TCRx Therapeutics Co.Ltd18
尚未招募
不适用
Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 MutationNCT07286292Institut de Recherches Internationales Servier (I.R.I.S.)10